Evaluation of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers
Phase 1 Multiple Dose Trial to Assess the Safety, Tolerability and Efficacy of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy volunteer is ≥ 18 years of age with BMI of 18-32
- Females could not be pregnant or breast feeding and had to be using birth control
- Must have regular bowel habits, typically producing at least 1 daily bowel movement
Exclusion Criteria:
- Screening 12-lead ECG demonstrating QTc interval >430 msec for males and >450 msec for females, or any cardiac rhythm disorder considered by the Investigator to be clinically relevant
- History or presence of gastrointestinal conditions
- Positive drug screen for substances of abuse
- Positive results for HIV, hepatitis B, or hepatitis C
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CLP 15 g QD
Cross-Linked Polyelectrolyte (CLP) study medication delivered immediately before bedtime
|
CLP was administered orally, in capsules, for 7 consecutive days.
|
|
Experimental: CLP 7.5 g BID
Cross-Linked Polyelectrolyte (CLP) Study medication delivered b.i.d.
one hour before breakfast and dinner
|
CLP was administered orally, in capsules, for 7 consecutive days.
|
|
Experimental: CLP 5 g TID
Cross-Linked Polyelectrolyte (CLP) Study medication delivered t.i.d.
one hour before breakfast, lunch and dinner
|
CLP was administered orally, in capsules, for 7 consecutive days.
|
|
Experimental: CLP 3.75 g QID
Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d on hour before breakfast, lunch, dinner and immediately before bedtime
|
CLP was administered orally, in capsules, for 7 consecutive days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in fecal sodium content
Time Frame: Baseline (Days 3-6) vs. Treatment (Days 10-13)
|
The primary endpoint was sodium removal from the stool compared between the Baseline period and the Treatment Period.
|
Baseline (Days 3-6) vs. Treatment (Days 10-13)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shanthini A. Daniel, MD, Jasper Clinic, Inc.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- CTST-16
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.